. Author manuscript; available in PMC: 2016 Jun 1.

Published in final edited form as: Toxicol Appl Pharmacol. 2015 Apr 10;285(2):136–148. doi: 10.1016/j.taap.2015.03.029

Table 5.

Effect of acrolein treatment on organ level of reduced glutathione (GSH).

		Time (h)
	Baseline	1	4	24
WT		% baseline
Heart	1.69±0.33	127.3±7.3^*	107.4±15.4	82.0±13.0
Stomach	3.67±0.22	63.8±4.4^*	74.8±4.5	75.4±7.0
Liver	6.74±0.16	106.0±4.2	87.3±6.6	104.4±6.7
GSTP-null		% baseline
Heart	1.93±0.31	81.3±5.8^†	108.1±4.3	83.0±11.0
Stomach	5.14±0.90	53.5±4.0^*	103.1±6.9	74.9±8.4
Liver	7.47±0.29	100.6±6.2	95.9±8.0	104.4±6.7

Acrolein exposure was 5 mg/kg bwt (p.o.). Baseline GSH level is μmol GSH/g tissue wet weight. GSH values are presented as a percentage of baseline at post-acrolein treatment points. Data are mean ± SEM

p<0.05 vs. baseline

^†

0.10>p>0.05 vs. baseline; N=6-8 mice/group.